Used in research and development of therapies targeting immune regulation, particularly in oncology and chronic inflammatory diseases. Binds to CD200, a cell surface glycoprotein that modulates immune responses, helping to disrupt immunosuppressive signals in the tumor microenvironment. Investigated for potential in treating hematologic malignancies such as chronic lymphocytic leukemia (CLL) and multiple myeloma by enhancing immune system recognition and attack of cancer cells. Also serves as a reference standard in immunoassays and antibody development workflows.